FOLH1 and metastatic malignant neoplasm in the lymph nodes: However, Ingvar et al., 2022, reported lower sensitivity (26%) due to small-sized metastases, but high specificity (96%) for 18F-PSMA-1007 PET/CT in the primary staging of lymph node metastases in intermediate- and high-risk PCa [30].